The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
 
J. Randolph Hecht
No Relationships to Disclose
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; MedImmune; Merck; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; BeiGene; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; Hutchison MediPharma; Ignyta; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Merck; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Rgenix; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Takeda; Tarveda Therapeutics; Tarveda Therapeutics; Tesaro; Tocagen; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Raid Aljumaily
No Relationships to Disclose
 
Deborah J.L. Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Karen A. Autio
Research Funding - ARMO BioSciences (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Milind M. Javle
No Relationships to Disclose
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Annie Hung
Employment - ARMO BioSciences
 
Peter Van Vlasselaer
Employment - ARMO BioSciences
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences
 
Joseph Leveque
Employment - ARMO BioSciences; EMD Serono
Leadership - ARMO BioSciences; EMD Serono
 
Martin Oft
Employment - ARMO BioSciences
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)